This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Forman, M. B. Articles by Virmani, R. Search for Related Content PubMed PubMed Citation Articles by Forman, M. B. Articles by Virmani, R.

Circulation, Vol 78, 202-213, Copyright © 1988 by American Heart Association

ARTICLES

Glutathione redox pathway and reperfusion injury. Effect of N- acetylcysteine on infarct size and ventricular function

MB Forman, DW Puett, CU Cates, DE McCroskey, JK Beckman, HL Greene and R Virmani
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Glutathione peroxidase is an important enzyme in the degradative cascade of reactive oxygen free radicals. N-Acetylcysteine (NAC) is a low molecular weight compound that has been used clinically to replenish glutathione. To assess the role of the glutathione redox pathway on reperfusion injury, 23 animals underwent 90 minutes of proximal left anterior descending coronary artery occlusion followed by 24 hours of reperfusion with the administration of NAC (n = 11) or saline (n = 12) beginning 30 minutes into occlusion and continuing for 3 hours after reperfusion. Regional ventricular function was measured with contrast ventriculography, and regional myocardial blood flow was determined with microspheres. At 24 hours, the area at risk was defined in vivo with Monastral Blue, and the area of necrosis was defined by incubation in triphenyltetrazolium. Biopsies were taken from the ischemic and nonischemic zones to determine levels of total glutathione, superoxide dismutase and glutathione peroxidase activity, and reactivity to thiobarbituric acid, an index of lipid peroxidation. The rate-pressure product and myocardial blood flow were similar in the two groups throughout the study. No significant differences were noted in infarct size expressed as a percentage of the area at risk (28.6 +/- 5.3% vs. 36.6 +/- 6.0%) and of the total left ventricle (14.4 +/- 3.2% vs. 16.5 +/- 3.1%), and no differences were noted between the two groups on examination of the ischemic subendocardium by light and electron microscopy. Both groups exhibited similar degrees of dyskinesis during occlusion; however, treated animals showed significant improvement in regional radial shortening at 3 hours (3.4 +/- 2.4% vs. -2.4 +/- 2.1%, p less than 0.02) and 24 hours (9.2 +/- 2.2% vs. -2.5 +/- 6.3%, p less than 0.001) after reperfusion. No differences were present in total glutathione, thiobarbituric acid reactivity, or superoxide dismutase and glutathione peroxidase activity in the ischemic zones of the two groups. This study suggests that N- acetylcysteine treatment before reperfusion may reduce myocardial stunning but does not limit myocyte death after reperfusion.

This article has been cited by other articles:

				R. Sethi, A. Adameova, K. S. Dhalla, M. Khan, V. Elimban, and N. S. Dhalla Modification of Epinephrine-induced Arrhythmias by N-Acetyl-L-Cysteine and Vitamin E Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2009; 14(2): 134 - 142. [Abstract] [PDF]

				W. L. Baker, M. W. Anglade, E. L. Baker, C. M. White, J. Kluger, and C. I. Coleman Use of N-acetylcysteine to reduce post-cardiothoracic surgery complications: a meta-analysis Eur. J. Cardiothorac. Surg., March 1, 2009; 35(3): 521 - 527. [Abstract] [Full Text] [PDF]

				M. Ozaydin, O. Peker, D. Erdogan, S. Kapan, Y. Turker, E. Varol, F. Ozguner, A. Dogan, and E. Ibrisim N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study Eur. Heart J., March 1, 2008; 29(5): 625 - 631. [Abstract] [Full Text] [PDF]

				L. G. Kevin, E. Novalija, and D. F. Stowe Reactive Oxygen Species as Mediators of Cardiac Injury and Protection: The Relevance to Anesthesia Practice Anesth. Analg., November 1, 2005; 101(5): 1275 - 1287. [Abstract] [Full Text] [PDF]

				J. Sochman N-acetylcysteine in acute cardiology: 10 years later: What do we know and what would we like to know?! J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1422 - 1428. [Abstract] [Full Text] [PDF]

				R. Bolli and E. Marban Molecular and Cellular Mechanisms of Myocardial Stunning Physiol Rev, April 1, 1999; 79(2): 609 - 634. [Abstract] [Full Text] [PDF]

				K. Okubo, S. Kosaka, N. Isowa, T. Hirata, S. Hitomi, J. Yodoi, M. Nakano, and H. Wada AMELIORATION OF ISCHEMIA-REPERFUSION INJURY BY HUMAN THIOREDOXIN IN RABBIT LUNG J. Thorac. Cardiovasc. Surg., January 1, 1997; 113(1): 1 - 9. [Abstract] [Full Text]

				M. A. Arstall, J. Yang, I. Stafford, W. H. Betts, and J. D. Horowitz N-Acetylcysteine in Combination With Nitroglycerin and Streptokinase for the Treatment of Evolving Acute Myocardial Infarction : Safety and Biochemical Effects Circulation, November 15, 1995; 92(10): 2855 - 2862. [Abstract] [Full Text]

				W. Chen, S. Gabel, C. Steenbergen, and E. Murphy A Redox-Based Mechanism for Cardioprotection Induced by Ischemic Preconditioning in Perfused Rat Heart Circ. Res., August 1, 1995; 77(2): 424 - 429. [Abstract] [Full Text]

				M. V. Cohen Free Radicals in Ischemic and Reperfusion Myocardial Injury: Is this the Time for Clinical Trials? Ann Intern Med, December 1, 1989; 111(11): 918 - 931. [Abstract] [PDF]